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Poor adherence is a major problem in patients with manic episodes that impairs
functionality and has unknown effects on oxidative stress. The objective of this study
was to analyze the relationship between adherence to medication, severity of symptoms
and oxidative stress in a sample of patients with a first episode of mania. A longitudinal,
6-month study was performed in 60 patients, who were classified as adherent and
non-adherent to medication (mainly antipsychotics). Blood levels of oxidative stress
parameters and expression of the antioxidant nuclear transcription factor NRF2 in
mononuclear cells of peripheral blood were assessed at baseline and at the end
of follow-up. In addition, clinical symptoms and functioning were evaluated. Linear
multivariate regression was used to determine the relationship between adherence,
oxidative stress, and clinical symptoms. Finally, 44 patients completed follow-up. The
results of this study showed that at 6-month follow-up, adherence was significantly
associated with better functioning and reduced clinical symptoms. Additionally, more
severe symptoms were associated with increased levels of oxidative stress and
antioxidant parameters. At study completion, non-adherents exhibited greater levels
of antioxidants than adherent patients. In conclusion, poor adherence to medication
is associated with a poorer prognosis in the medium term and causes increased
antioxidant response.
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INTRODUCTION
Bipolar disorder (BD) is a chronic disease that causes greater disability than cancer. It is estimated
that 57% of BD patients are partially or totally non-adherent to medication (1). This lack of
adherence causes a worsening of symptoms and increases of the risk for relapse, which may be
related to neurobiological disbalance (2–5).
The physiopathology of BD has been the subject of intensive research, with a special focus on
the search for biomarkers (6–8) that enable early diagnosis and a more accurate prognosis (9).
Several studies agree about the analysis of total antioxidant status (TAS), which considers the
cumulative effect of all antioxidant compounds present in plasma (10, 11). TAS has been proven
to be decreased in patients with a first episode of mania (FEM) compared to healthy subjects (12).
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This parameter, that reflects disbalance in oxidative stress,
has been related to worse clinical status of patients (13). In
this context, nuclear factor erythroid 2-related factor-2 (NRF2)
activity has a relevant role. In brief, NRF2 transcription factor
regulates the expression of genes encoding antioxidants and
detoxification enzymes by binding to a specific DNA sequence
known as ARE (Antioxidant Response Element), found in the
promoter regions.
Evidence has been recently provided that medication for BD
has antioxidant effects. Thus, lithium—the first-choice therapy
for BD- (14) has neuroprotective effect that reduces oxidative
damage (15). In relation to antipsychotic drugs—one of the
most powerful drugs for acute manic episodes (16)–, there is
evidence that risperidone has an antioxidant effect (17). In animal
models, paliperidone has been observed to regulate endogenous
antioxidant pathways by preventing a decrease in antioxidant
levels (18) or inducing its increase (19).
All this considered, and given that poor adherence is related
to a higher risk for relapse and a worse prognosis of mania (20),
we hypothesized that poor adherence and oxidative stress may
be associated.
The objective of this 6-month follow-up study was to
investigate the relationship among drug therapy, adherence,
oxidative stress, and clinical symptomatology in a sample of
subjects with a FEM. Our hypothesis was that adherent patients
would have a higher antioxidant capacity, which will be reflected
in a better clinical status.
MATERIALS AND METHODS
Subjects
The sample was composed of 60 patients with a FEM admitted
to the Department of Psychiatry of Araba University Hospital,
Spain. Inclusion criteria were: (1) patients with a first episode of
pure or mixed mania according to DSM IV-TR criteria (SCID-I
and II) (21), (2) age of 12–40 years at disease onset, and (3) being
fluent in Spanish. Exclusion criteria were: (1) mental retardation
(assessed by DSM-IV-TR), (2) history of cranial trauma with loss
of consciousness, (3) disease that causes mental health problems,
(4) pervasive developmental disorders (PDD) and (5) pregnancy
or breastfeeding.
The study was approved by the local Ethics Committee.
Informed consent was obtained from all patients in accordance
with the Declaration of Helskinki II. In subjects <18 years of
age, informed consent was obtained from their legal tutors after
subjects agreed to participate in the study.
Design and Clinical Assessment
This prospective longitudinal study involved the collection of
blood samples and the performance of clinical assessments at
baseline and at 6 months. Clinical evaluation was carried out
by psychiatrists using the following instruments: the Spanish
version of the Positive and Negative Syndrome Scale (PANSS),
which measures the severity of symptoms of psychosis (22);
the Hamilton Rating Scale for Depression (HRSD) (23); Young
Mania Rating Scale (YMRS) (24); the Global Assessment
of Functioning (GAF) (25) and the Global Assessment of
Functioning in Children (CGAS) (26)—when appropriate–,
which assesses functioning and severity of symptoms; and the
Clinical Global Impression rating scale (CGI) (27), which assesses
the severity and overall improvement of symptoms. Adherence to
medication at the end of follow-up was assessed using Morisky-
Green scale (28), by which patients were classified as adherent
or non-adherent. This self-reported scale includes four yes/no
questions rated on a 0–4 scale, considering patients who obtain
0 points as adherent and as not adherent those who obtain a 1+
score (29).This classification was subsequently confirmed by the
patient’s treating physician.
Sample Collection and Preparation
Venous blood samples (10mL) were collected early in the
morning (between 8:00 and 9:00) after fasting overnight, by the
nursing staff in polypropylene EDTA-containing tubes. Fresh
blood was stored at 4◦C until processing about 1 h. later (see
Supplementary Material for more details).
Biochemical Measurements in Plasma
Nitrites (NO−2 ) the stable metabolites of free radical nitric
oxide, were measured by the Griess method (30). Levels of
lipid peroxidation (TBARS) were determined by Thiobarbituric
Acid Reactive Substances (TBARS) assay (ref. 10009055, Cayman
Chemical Europe), and the level of TAS was determined using
the Antioxidant Assay Kit (ref. 709001, Cayman Chemical
Europe) (For more details about the experimental procedure see
Supplementary Material).
Biochemical Measurements in Peripheral
Blood Mononuclear Cells (PBMCs)
The activity of NRF2 was measured in nuclear extracts using
a commercially available NRF2 Transcription Factor Assay
Kit (ref. 600590, Cayman Chemicals) following manufacturer’s
instructions. A procedure based on the modified Schreiber
method was used for the preparation of nuclear extracts (31).
Statistical Analysis
Once normality of sociodemographic and clinical data was
confirmed, descriptive analysis was performed. Results were
expressed as means± SD and percentages.
Differences between categorical variables inter-groups were
assessed by the Chi-squared test. For continuous variables,
differences were analyzed using the Student’s t-test for
independent samples. Intra-group differences in oxidative
stress during follow-up were assessed using analysis of variance
(ANOVA) with repeatedmeasures. Backward stepwise regression
were used to determine the relationship between adherence to
medication and oxidative stress and symptoms. The same model
was used to assess the relationship between symptoms and
oxidative stress in the entire sample and determine potential
associations among oxidative stress parameters. As CGI score is
an ordinal variable, ordinal regression analysis was performed to
assess the relationship between adherence and CGI score.
Models were controlled for potential confounding factors;
significant confounding variables were included in the final
models. When a (significant) confounding variable was included
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in a model, the interaction of independent variables with these
confounding variables was also included.
Data are expressed as beta coefficients with p-values and the
corresponding 95% confidence interval. Statistical analysis was
performed using SPSS v23.0. A p-value < 0.05 was considered
statistically significant.
RESULTS
Forty-four of the 60 initial subjects completed follow-up andwere
classified either as adherent (n = 28) or non-adherent (n = 16).
Patients lost to follow-up were excluded from the final sample (n
= 16). The characteristics of the sample are displayed in Table 1.
At 6 months, the use of cannabis was significantly higher among
non-adherent patients, as compared to adherent patients (χ² =
7.06, p < 0.05). No differences were observed in relation to the
treatment administered.
Relationship Between Adherence to
Medication and Clinical Symptoms
Adherence to medication at 6 months showed a significant direct
relationship with functioning as assessed by GAF (B= 11.36, 95%
CI: 4.51–18.22, p < 0.01; after adjusting for alcohol an cannabis
consumption at baseline, cannabis consumption at 6months, sex,
and education) and an inverse relationship with symptoms as
measured by total PANSS (B = −9.32, 95% CI: −15.49 to −3.14,
p < 0.01; after adjusting for education and alcohol consumption
at baseline), general PANSS (B=−4.41, 95% CI:−7.77 to−1.06,
p < 0.05; after adjusting for education, alcohol consumption at
baseline and cannabis consumption at 6 months), HRSD (B =
−3.75, 95% CI: −6.94 to −0.56; p < 0.05) and CGI severity scale
(OR = 4.64, 95% CI: −2.795 to −0.272, p < 0.05; after adjusting
for education).
Relationship Between Oxidative Stress and
Clinical Symptomatology in the Sample
During Follow-Up
At 6-month follow-up, HRSD yielded a significant positive
relationship with TAS (B = 0.10, 95% CI: −0.002 to −0.21,
p = 0.05; after adjusting for alcohol consumption at baseline),
whereas the GAF scale demonstrated an inverse significant
relationship with this antioxidant parameter (B=−0.57, 95% CI:
−0.10 to−0.01, p < 0.05; after adjusting for alcohol and tobacco
consumption at baseline). CGI severity scale also presents a
positive relationship with TAS, although in this case it was
not significant (B = 0.346, 95% CI: −0.06–0.76, p = 0.083).
Furthermore, negative PANSS scores showed a significant direct
relationship with NO−2 values (B = 1.86, 95% CI: 0.14–3.60, p <
0.05; after adjusting for alcohol consumption at baseline).
The association between antioxidant capacity and the level of
oxidative stress is supported by the direct relationship between
TBARS and TAS parameters (B = 0.82, 95% CI: 0.22–1.42, p <
0.01), where antioxidant levels increased in response to increased
oxidative damage.
Relationship Between Adherence to
Medication and Oxidative Stress
Both, the adherent and non-adherent group exhibited a
significant reduction in TAS (F = 178.99, p < 0.01; F = 29.14,
p < 0.01, respectively) and a significant increase in NO−2 at 6-
month follow-up (F = 8.44; p < 0.01; F = 5.42, p < 0.05). The
non-adherent group presented a significantly lower decrease in
TAS levels (t = −2.08, p < 0.05; Figure 1) and a non-significant
rise of NRF2 activity and oxidative stress levels (TBARS, NO−2 )
compared to the adherent group at the end of follow-up.
There was a significant inverse relationship between
adherence and TAS levels at 6- month follow-up, with an
increased antioxidant capacity in patients with poor therapeutic
compliance (B = −1.46; 95% CI: −2.60 to −0.32, p < 0.05; after
adjusting for tobacco consumption at 6 months).
DISCUSSION
In the light of the results obtained, efforts should be made
to ensure treatment adherence in BD patients. Treatment
adherence results in an improvement of symptoms, which
has been associated with the reduction of oxidative stress.
Therefore, as non-adherent patients have more severe symptoms,
their oxidative stress increases and their antioxidant capacity
augments as an adaptive response of the body. This phenomenon
is demonstrated by the direct relationship observed in our study
between TBARS and TAS at 6 months in the entire sample. A
previous study (17) in 51 patients with a first episode of psychosis
showed that levels of oxidative stress diminished following the
administration of risperidone. We obtained similar results for
FEM patients who underwent longer follow-up and found that
adherence is crucial when assessing response to treatment based
on clinical and biological parameters such as oxidation. Non-
adherence to medication is especially important in patients with
bipolar disorder (1). Conversely to our initial hypothesis, TAS
levels were higher in non-adherent patients as compared to
adherent patients at the end of follow-up. We hypothesize that
this phenomenon may be associated with small, non-significant
increases in oxidative stress, thereby supporting the relationship
between TBARS and TAS. The patients who did not take
correctly their prescriptions had worse clinical outcomes, which
is consistent with previous studies (4, 5). Additionally, non-
adherent patients maintained higher antioxidant levels in the
long term. To our knowledge, this is the first study that shows
the relationship between lack of adherence and higher TAS in
the long term. Increased oxidative stress (manifested as higher
levels of TAS) probably triggers a complex sequence of events
that lead to the migration of NRF2 into the nucleus, where it
binds to ARE, thereby increasing the antioxidant capacity of the
patient (32). In our sample there was a non-significant increase
in NRF2. As shown by other authors, to maintain homeostatic
balance, NRF2 remains inactive in the cytoplasm until oxidative
stress conditions emerge (33, 34).
Conflicting results have been obtained in a variety of studies
on the antioxidant effect of treatments based on typical and
atypical antipsychotics and lithium, and how they regulate
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TABLE 1 | Sociodemographic characteristics and oxidative parameters in a FEM sample classified by adherence to medication.
Sociodemographic characteristics Total patients (N = 44) Adherent patients (N = 28) Non-adherent patients (N = 16)
Age in years, n (SD) 27.09 (7.24) 28.36 (6.8) 25.25 (7.85)
Sex (M,/F), n (%) 71.1 /28.9 78.6 /21.4 58.8 / 41.2
COHABITANTS
Parents and siblings 51.2 46.2 56.2
Relatives 4.7 7.6 0
Alone 16.3 23.1 6.3
Partner and children 14.0 15.4 12.5
Roommates 11.5 7.7 18.7
Institutionalized 2.3 0 6.3
SOCIOECONOMIC STATUS, (%)
1 (lowest) 7.1 11.5 0
2 14.3 3.8 33.3
3 45.2 46.2 40
4 21.4 23.1 20
5(highest) 11.9 15.4 6.7
OCCUPATION, (%)
Medical or disability leave 4.7 3.7 6.3
Student 23.3 22.2 25
Unemployed 18.6 7.4 37.5
Active 53.5 66.7 31.3
Substance use (%) Baseline At 6 months Baseline At 6 months Baseline At 6 months
Tobacco 27.3 20.9 28.6 25.9 25 12.5
Alcohol 59.1 32.6 60.7 33.3 56.3 31.3
Cannabis 18.2 7 10.7 0 31.3 18.8
Other substances 15.9 0 7.1 0 31.3 0
TYPE OF MEDICATION, (%)
Atypical antipsychotic 77.7 51.1 85.7 51.9 68.8 56.3
Atypical antipsychotic and lithium 20 17.7 14.3 18.5 31.3 18.8
Lithium 0 11.1 0 14.8 0 6.3
Others 0 15.5 0 14.8 0 18.8
OXIDATIVE STRESS PARAMETERS
TAS, mM (SD) 7.65 (1.02) 2.5 (1.83) 7.57 (1.12) 2.04 (0.89) 7.75 (0.90) 3.25 (2.64)
TBARS, uM (SD) 1.61 (0.75) 1.9 (1.04) 1.66 (0.74) 1.75 (0.97) 1.53 (0.80) 2.21 (1.14)
NO−2 , Um (SD) 19.4 (9.88) 38.5 (29.66) 19.61 (9.32) 36.72 (29.42) 18.98 (11.71) 41.67 (31.83)
NRF2, A.U (SD) 0.40 (0.17) 0.57 (0.35) 0.39 (0.21) 0.49 (0.25) 0.41 (0.13) 0.64 (0.42)
oxidative stress in preclinical studies (18, 19, 35–39). In our
study, an increase in oxidative stress levels and a decrease in
antioxidant response were noted in the two groups at 6 months,
regardless of the medication administered. As shown in previous
studies, oxidative stress diminished in the patients who took
their prescriptions correctly (17). Surprisingly, oxidative stress
also decreased at 6 months in non-adherent patients, something
that had not been ever reported, to our knowledge. Yet, a
direct relationship was found between clinical symptoms and
oxidative stress and antioxidant capacity at 6 months. This
has been shown in patients with a first episode of psychosis
after 6-month follow (40), and in patients with early psychosis
after 2-year follow- up (13). However, this association was not
observed in other studies based on 11-week follow-up (17),
or 6 weeks follow-up (41). Antipsychotic therapy may have
positive effects on oxidation, as it may have intrinsic antioxidant
properties in the short term not related to symptoms. However,
after 6 months, to achieve oxidative balance in non-adherent
patients, the body reduces oxidation by increasing TAS. The
reason for this phenomenon may be that adherent patients
reach oxidative balance faster than non-adherent patients. This
hypothesis is supported by the results of Noto et al., which
showed that oxidative balance at 11 weeks was not related
to symptom improvement (17). In contrast, our results after
6-month follow-up reflect an association between antioxidant
status and clinical severity. More specifically, antioxidant status
was found to be related to depression, negative symptoms, and
functional outcome.
Frontiers in Psychiatry | www.frontiersin.org 4 March 2019 | Volume 10 | Article 162
García et al. Association Between Adherence and Oxidative Stress
FIGURE 1 | Mean differences ± SD in biomarkers between adherent and non adherent patients at 6-month follow-up. & P < 0.05, && P < 0.01 in the intra-group
analyses between baseline and 6-months follow-up. # P < 0.05 between adherent and non adherent patients at 6-months follow-up.
This study has some limitations. First, the high number
of patients lost to follow-up at 6 months. This may be due
to the characteristics of patients with a FEM, whose level
of awareness is generally low or nonexistent. Second, we
could not assess the neuroprotective effect of lithium due
to the small proportion of patients who received lithium
therapy. Third, only indirect methods based on interviews
and reports from clinicians were used to assess adherence.
However, most studies use indirect methods to assess
adherence as compared to direct methods (77 vs. 23%,
respectively) (42).
In sum, contrary to what has been previously demonstrated
in the short term, oxidative stress and antioxidant capacity
might not be directly modulated by medication at 6 months,
but indirectly by symptoms. Thus, adherence to medication
may have an indirect mediation effect on oxidative stress.
The mechanism is as follows: with the medication, clinical
status improves, which results in a lower activation of
the antioxidant system. These 6-month follow-up results
shed light on the role of oxidative status in psychiatric
diseases, its relationship with clinical status, and the effects
of medication on clinical status and antioxidant capacity.
Larger, long-term studies with repeated measures at short and
long term follow ups are needed to validate the results of
this study and confirm the importance of good adherence
to medication.
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